| Prev Close | 273.84 |
| Open | 274.31 |
| Day Low/High | 267.67 / 274.54 |
| 52 Wk Low/High | 223.25 / 374.99 |
| Volume | 1.29M |
Biogen Inc. (BIIB)
271.00
2.80
1.00
NASDAQ
| Exchange | NASDAQ |
| Shares Outstanding | 153.88B |
| Market Cap | 42.14B |
| P/E Ratio | 9.03 |
| Div & Yield | N.A. (N.A) |
Stepping Carefully Into the Second Quarter
The potential for so-so earnings results among the S&P 500 and an initial lackluster response to IPOs could cause investors to pause a bit after a strong first three months of 2019.
How I Use Options to Mitigate Risk and Create Income
Buy-write strategies give you confidence to 'buy the dip' while also adding an extra income stream.
Future Brightens for 2 Small Biotech Stocks
The biotech sector isn't for the faint of heart, but these two companies issued promising news this week.
Powell and Company Can Influence the Macro, but Not the Micro
All the money in the world cannot change the fact that rising stock prices and falling earnings make the market more expensive.
Volatile Biogen Stock Plunges $90: Here's the Trade I'm Considering
Biogen shareholders are taking a beating on cancellation of trials for its Alzheimer's drug candidate.
What's Next for Biogen After It Terminates Trials for Alzheimer's Drug?
Biogen has to now be considered a more likely buyout target given the breadth of its product portfolio.
Biogen Could Go Either Way - Mixed Indicators and Charts
Let's check to see what can be gleaned.
Sloppy Earnings, China's Economy, AMD Earnings Preview: Market Recon
What we have seen of late from a number of chip producers really might be interpreted as pre-recessionary.
Jim Cramer: The Long-Awaited Drug Company Consolidation Has Begun
And it is happening not a moment too soon.
Biogen's Slump Is Likely to Continue
Avoid the long side of Biogen as the October low is likely to be tested or broken in the days ahead.
The Real Money Post-Industrial Average Has Jumped 11% So Far This Year
For the month of November RMPIA climbed 1.2% month over month.
Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half
Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
Big Swings in Biogen Make It Hard to Take New Positions
Short-term price action may be volatile, but this name is still bullish long term.
The Race to Cure Alzheimer's is On: These Are the Forerunners
Top pharmaceutical companies are paving the way to a cure for Alzheimer's, a degenerative disease that is affecting millions around the world.
Jim Cramer: We've Got an Extremist Market
Don't buy up when there's nothing but rampant pin action.
2 Small Biotechs I Like in the Second Half
Adamis Pharmaceuticals and Pieris Pharmaceuticals are names to watch.
Biogen Stock: A Long-Term Bullish Perspective
After Friday's surge another look at BIIB is warranted.
Jim Cramer: The Strength in Pharma, Health Care and Real Estate Is Transient
The seemingly terrific rationales for strength in these economically sensitive sectors seem glib until the bigger global economic issues get resolved.
Video: Jim Cramer on the Jobs Report, Tariffs and Biogen
TheStreet's founder and Action Alerts PLUS Portfolio Manager Jim Cramer weighs in on Friday's trending market topics from the floor of the New York Stock Exchange.
Biogen, Eisai Aim to Bring Their Alzheimer Drug to Market
Real Money reveals the crucial component Biogen got right in this trial and what it plans for the drug next.
Biotech Stocks Rally on Biogen's Landmark Test
Investors might be finally recognizing the hidden value of the firms' drug research and development.
Midday Musings
At midday tech, biotech ( dragging the group higher), homebuilders and energy are leading to the upside. There are really no large underperformers - though on a relative sense, autos, cap goods and semis are trailing. Banks fell initially, on the "d...
Biogen: Let the Situation Cool Off a Bit Before Buying
There are issues in the study that are keeping some buyers cautious and causing selling into the early strength.
Gilead Sciences Is Displaying a Bullish Long-Term Pattern
This biotech's weekly chart is very encouraging.
Exposure to Feverish Biogen Should Give These 2 Biotech ETFs Booster Shots
First Trust NYSE Arca Biotechnology Index Fund and iShares Nasdaq Biotechnology ETF look like two ways to catch the rally in Biogen.
Biogen Soars, and It May Signal a Breakout Gap to Further Gains
My longer-term price target is now $416.
